NTC Pharma has acquired Pharmathen for an undisclosed amount. Pharmathen, founded in 1969, is a vertically integrated developer of complex drug delivery technologies, with a strong focus on long-acting injectables (LAI), sustained release, and ophthalmic formulations. This acquisition significantly enhances NTC Pharma's capabilities within the pharmaceutical sector.
Pharmathen boasts an extensive and advanced pipeline, comprising over 100 commercialized products. These are manufactured in its US FDA and EU-approved facilities in Greece, serving 250 customers and patients in more than 90 countries worldwide. The company is recognized for its commitment to innovation, holding three fully certified technological platforms that support its Long-Acting Therapeutic Technologies (LATTs) and aim to improve treatment compliance and product Life Cycle Management. It ranks among Europe's top 50 pharmaceutical research companies and is a leading private sector investor in Greek R&D.
The acquisition is strategically significant for NTC Pharma, providing immediate access to Pharmathen's specialized expertise in complex drug delivery systems and its robust R&D infrastructure. This integration is expected to broaden NTC Pharma's product portfolio and geographic reach, leveraging Pharmathen's established presence in major markets and extensive partner network. Synergies are anticipated through the combination of NTC Pharma's existing operations with Pharmathen's innovative platforms and manufacturing capabilities, aiming to deliver enhanced value to patients and customers globally.
This transaction marks a key step in NTC Pharma's growth strategy, consolidating advanced pharmaceutical development and manufacturing capabilities. The combined entity is positioned to accelerate innovation in critical therapeutic areas, offering a wider range of optimized pharmaceutical products and improving access to affordable medicines on a global scale.